» Articles » PMID: 16704648

A 52-week Randomized Safety Study of a Calcipotriol/betamethasone Dipropionate Two-compound Product (Dovobet/Daivobet/Taclonex) in the Treatment of Psoriasis Vulgaris

Overview
Journal Br J Dermatol
Specialty Dermatology
Date 2006 May 18
PMID 16704648
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The calcipotriol/betamethasone dipropionate two-compound product Dovobet/Daivobet/Taclonex(LEO Pharma A/S, Ballerup, Denmark) has been shown to be safe and effective in the treatment of psoriasis for up to 8 weeks. As psoriasis is a chronic disease, long-term treatment may be required, so there is a need to investigate the safety of its use over a longer period of time.

Objectives: To investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks in the treatment of patients with psoriasis.

Methods: Patients (n = 634) were randomized double-blind to treatment with: (i) 52 weeks of the two-compound product (two-compound group); (ii) 52 weeks of alternating 4-week periods of the two-compound product and calcipotriol (alternating group); or (iii) 4 weeks of the two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Treatments in all groups were used once daily when required.

Results: Adverse drug reactions (ADRs) occurred in 45 (21.7%) patients in the two-compound group, 63 (29.6%) in the alternating group and 78 (37.9%) in the calcipotriol group. The odds ratio for an ADR in the two-compound group relative to the calcipotriol group was 0.46 (95% confidence interval 0.30-0.70; P < 0.001). ADRs of concern associated with long-term topical corticosteroid use occurred in 10 (4.8%) patients in the two-compound group, six (2.8%) in the alternating group and six (2.9%) in the calcipotriol group; those with the highest incidence were skin atrophy, occurring in four (1.9%), one (0.5%) and two (1.0%) patients, respectively, and folliculitis, in three (1.4%), one (0.5%) and no patients, respectively.

Conclusions: Treatment with the two-compound product for up to 52 weeks appears to be safe and well tolerated whether used on its own or alternating every 4 weeks with calcipotriol treatment.

Citing Articles

Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older.

Kedra K, Reich A Drug Des Devel Ther. 2024; 18:5827-5839.

PMID: 39670279 PMC: 11636291. DOI: 10.2147/DDDT.S240867.


Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature.

Fargnoli M, De Simone C, Gisondi P, Pellacani G, Calzavara-Pinton P Dermatol Ther (Heidelb). 2023; 13(11):2527-2547.

PMID: 37737941 PMC: 10613180. DOI: 10.1007/s13555-023-01024-9.


Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results.

Hong J, Wu P, Qin A, Huang Y, Tseng K, Lai C Pharmaceutics. 2022; 14(10).

PMID: 36297594 PMC: 9608911. DOI: 10.3390/pharmaceutics14102159.


Calcipotriene/betamethasone dipropionate foam: primary evidence supporting its use in patients with psoriasis vulgaris. A narrative review.

Narbutt J, Czajkowski R, Lesiak A, Owczarek W, Reich A, Szepietowski J Postepy Dermatol Alergol. 2021; 38(5):727-733.

PMID: 34849116 PMC: 8610051. DOI: 10.5114/ada.2021.110062.


Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review.

Papp K, Dhadwal G, Gooderham M, Guenther L, Turchin I, Wiseman M Dermatol Ther. 2021; 34(6):e15104.

PMID: 34418251 PMC: 9286633. DOI: 10.1111/dth.15104.